Agios’ second shot at sickle cell disease falls short

July 21, 2026 11:14 AM EDT R&D Agios’ sec­ond shot at sick­le cell dis­ease falls short Lei Lei Wu News Reporter Agios said it is drop­ping a next-gen­er­a­tion sick­le cell dis­ease drug af­ter lack­lus­ter re­sults from a mid-stage tri­al. The drug, known as tebapi­vat, rep­re­sent­ed Agios’ … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER